Théa and OliX partner on RNAi therapies for AMD

19 March 2019

South Korean RNAi therapeutics developer OliX Pharmaceuticals (Kosdaq: 226950) has signed a license and collaboration agreement with Théa Open Innovation, a sister company of France-headquartered Laboratoires Théa, to develop and commercialize OLX301A, a novel treatment for age-related macular degeneration (AMD).

Under the agreement, OliX receives a non-refundable and non-creditable upfront payment of 2 million euros ($2.3 million) and is eligible to receive milestone payments based on the achievement of clinical milestones, plus royalty for the development and commercialization.

Dong-ki Lee, the founder and chief executive of OliX, stated: "OliX's cp-asiRNA platform technology is an RNAi platform optimal for the development of ocular therapeutics, which can circumvent potential side effects arising from the existing siRNA technology. The collaboration with Théa proves that OliX's ophthalmology RNAi platform has been recognized in global pharmaceutical market, and we will continue to expand pipelines for eye diseases."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK